Longer-term therapy with omalizumab has been shown to improve asthma and reduce exacerbations. Investigators looked at the short-term effects of the medication.
In children and adolescents with asthma, concomitant rhinitis is ubiquitous and intractable. But how the conditions are related is incompletely understood.